EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Couple-Based Carrier Screening: How Gene and Variant Considerations Impact Outcomes

Eric Lee iD, Kaylee Orton iD, Edward Kwan, Claire Faga, Trang Le, Ranad Shaheen, Vivek Nair, Simon Cliffe

Genes · 2025

DOI: 10.3390/genes16060671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Eric Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Genetics Department, Virtus Diagnostics, Suite 4, Level 1, 20-30 Blamey St, Revesby, NSW 2212, Australia. Hauptthemen laut MEDLINE: Genetic Carrier Screening, Genetic Testing. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The clinical utility of reproductive carrier screening varies based on the genes tested, variant reporting policies, and the screened patient population. This study aims to evaluate the outcomes of carrier screening among reproductive couples undergoing testing in a routine clinical setting.

Methods

A total of 1595 couples, primarily referred by reproductive endocrinology and infertility specialists, underwent couple-based carrier screening across 390 genes. Carrier states were assessed on a couple basis and reported only if a couple were at risk of having affected offspring. At-risk conditions were classified by severity, as well as their likelihood of clinical impact based on the specific variants detected in each at-risk couple. Secondary findings with potential personal utility were also evaluated.

Results

Among the screened couples, 4.2% were at risk of having a child with a genetic condition. When limited to high-clinical-impact results, the at-risk couple rate decreased to 1.0%, with 44% of these cases involving CFTR, SMN1, or FMR1. Secondary findings were identified in 1.7% of individuals.

Conclusions

Carrier screening for only CFTR, SMN1, and FMR1 will miss more than half of at-risk couples, underscoring the importance of broader carrier screening. Specific variants and their combinations can influence the predicted clinical impact of at-risk conditions, marking a key advantage of couple-based reporting. Secondary findings were common, highlighting the importance of discussing these potential findings during pre-test counselling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Carrier ScreeningGenetic TestingHumansFemaleMaleAdultFragile X Messenger Ribonucleoprotein 1Cystic Fibrosis Transmembrane Conductance RegulatorHeterozygoteGenetic Counseling

Stichwörter der Autor:innen

carrier screeningcystic fibrosisfragile X syndromeinfertilityspinal muscular atrophy

Substanzen

Fragile X Messenger Ribonucleoprotein 1Cystic Fibrosis Transmembrane Conductance RegulatorFMR1 protein, humanCFTR protein, human

Autor:innen und Institutionen

  • Molecular Genetics Department, Virtus Diagnostics, Suite 4, Level 1, 20-30 Blamey St, Revesby, NSW 2212, Australia.

ORCID-Profile: Eric Lee, Kaylee Orton

Zitieren

APA

Lee, E., Orton, K., Kwan, E., Faga, C., Le, T., Shaheen, R., Nair, V., & Cliffe, S. (2025). Couple-Based Carrier Screening: How Gene and Variant Considerations Impact Outcomes. Genes. https://doi.org/10.3390/genes16060671

Vancouver

Lee E, Orton K, Kwan E, Faga C, Le T, Shaheen R, et al. Couple-Based Carrier Screening: How Gene and Variant Considerations Impact Outcomes. Genes. 2025. doi:10.3390/genes16060671

BibTeX
@article{Lee2025,
  author = {Lee, Eric and Orton, Kaylee and Kwan, Edward and Faga, Claire and Le, Trang and Shaheen, Ranad and Nair, Vivek and Cliffe, Simon},
  title = {Couple-Based Carrier Screening: How Gene and Variant Considerations Impact Outcomes},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16060671}
}
Kostenlos starten →